Inverness Medical Innovations - Concateno plc, Further Announcement Regarding UK...

Inverness Medical Innovations - Concateno plc, Further Announcement Regarding
UK Takeover Code Share Dealing Disclosure Requirements.

WALTHAM, Mass., June 30 /PRNewswire-FirstCall/ -- In connection with its
proposed acquisition of London based, drugs of abuse testing company Concateno
plc, announced on June 5 2009, Inverness Medical Innovations, Inc. (NYSE: IMA)
has been requested by the UK Takeover Panel to remind Inverness shareholders
through this announcement of their dealing disclosure obligations under Rule
8.3 of the UK Takeover Code.

Dealing disclosure requirements of the UK Takeover Code

Under the provisions of Rule 8.3 of the UK Takeover Code, if any person is, or
becomes, "interested" (directly or indirectly) in one per cent (1%). or more
of any class of "relevant securities" of either IMA or Concateno, all
"dealings" in any "relevant securities" of that company (including by means of
an option in respect of, or a derivative referenced to, any such "relevant
securities") must be publicly disclosed by no later than 3.30 p.m. (London
time) on the London business day following the date of the relevant
transaction. This requirement will continue until the date on which the
proposed acquisition becomes effective or the proposals lapse or are otherwise
withdrawn, or on which the "offer period" otherwise ends. If two or more
persons act together pursuant to an agreement or understanding, whether formal
or informal, to acquire an "interest" in "relevant securities", they will be
deemed to be a single person for the purpose of Rule 8.3.

The numbers of "relevant securities" of Concateno and Inverness currently in
issue can be found on the Takeover Panel's website at
http://www.thetakeoverpanel.org.uk.

"Interests in securities" arise, in summary, when a person has long economic
exposure, whether conditional or absolute, to changes in the price of
securities. In particular, a person will be treated as having an "interest"
by virtue of the ownership or control of securities, or by virtue of any
option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the Takeover Code, which can also be
found on the Takeover Panel's website. If you are in any doubt as to whether
or not you are required to disclose a "dealing" under Rule 8, you should
consult the Takeover Panel whose contact details are:

Tel: +44 (0) 207 638 0129; Fax +44 (0) 207 236 7013; email:
info@thetakeoverpanel.org.uk.

About Inverness

By developing new capabilities in near-patient diagnosis, monitoring and
health management, Inverness Medical Innovations enables individuals to take
charge of improving their health and quality of life. Inverness' global
leading products and services, as well as its new product development efforts,
focus on infectious disease, cardiology, oncology, drugs of abuse and women's
health. Inverness is headquartered in Waltham, Massachusetts.

For more information about Inverness Medical Innovations, please visit our
website at http://www.invernessmedical.com.

For additional information on Concateno, please visit www.concateno.com

SOURCE Inverness Medical Innovations

Investor Relations: Doug Guarino, Director of Corporate Relations of
Inverness, +1-781-647-3900